Global Blood Therapeutics, Inc.

Portola Pharmaceuticals, Inc.

Uber Technologies, Inc.

Alexion Pharmaceuticals, Inc.

Qing Xu

Zhe Li

Anjali Pandey

Yonghong Song

Shawn M Bauer

Zhaozhong Jon Jia

Mukund Mehrotra

Jack W Rose

Calvin Wesley Yee

Wolin Huang

Brian Walter Metcalf

Brian Kane

Chandrasekar Venkataramani

Stephen L Gwaltney, Ii

Jason R Harris

Hing L Sham

Ming Yu

Lina Quattrocchio Setti

Miao Yu

Qi Chen

Casey Lawler

Linfeng Shi

Stephen L Gwaltney

Manuel Zancanella

Chul Yu

Carsten Alt

Peter Michael Rademacher

Peter Ng

Siddharth Kar

Nikhil Goel

Yuhki Yamashita

Brian Tolkin

Shahul Nilar

Sami Aref

Kobina N Dufu

Steven Richards

Matthew A Lardy

Jack Rose

James Partridge

Stephen L Ii Gwaltney

Ii Stephen L Gwaltney

Stephen L Gwaltney Ii

A network system dynamically determines a route, including start and end points, for vehicles in a transportation network. The transportation network receives a service request from a user of the transportation network including an origin location for the trip and a destination location for the trip. The transportation network then generates a waypoint plan for one or more vehicles, which includes the requested origin and destination in addition to any previously requested origins and destinations included in the vehicles current route. The network system then determines a directionality for each of the waypoints in the waypoint plan and retrieves candidate start and end points that have an associated directionality within a threshold angle of the directionality of each waypoint and are proximate to the waypoint. The network system evaluates each combination of retrieved candidate points to select a route for the vehicle.

Dynamically determining origin and destination locations for a network system

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Cycloalkyl pyrimidines as ferroportin inhibitors

The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Tricyclic compounds as histone methyltransferase inhibitors

The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. 

A computing system can implement pick-up location optimization by receiving trip requests and location data from computing devices of users and determining a specified region in which each requesting user is located. Each region can be associated with a plurality of eligible pickup locations. The computing system can score each of a plurality of eligible pickup locations based, at least in part, on (i) ETAs of vehicles to the pickup locations, and (ii) an amount of reduced time for utilizing each pickup location as opposed to the current location of the requesting user or a pick-up location specified by the requesting user. Based on the scoring, the computing system may then select (i) a trip pickup location to initiate the trip request, and (ii) a selected vehicle from the set of candidate vehicles to service the trip request.

Travel coordination system implementing pick-up location optimization

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Compounds and uses thereof for the modulation of hemoglobin

The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.

Inhibitors of protein kinases

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis. The compounds of Formula I and pharmaceutical salts thereof have the following structure: wherein R, R, R, X, X, X, X, Y, Y, and Yare as described herein.

Ferroportin inhibitors and methods of use

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

Modulators of hemoglobin

Growing community of inventors

Foster City, CA, United States of America

Qing Xu